Japan’s Ono Pharma focusing on building immuno-oncology portfolio with Opdivo
pharmafile | March 7, 2016 | News story | Sales and Marketing | Bristol-Myers Sqibb, Ono Pharma, immuno-oncology, opdivo
Japan’s Ono Pharmaceutical has said it is focused on building on its immuno-oncology portfolio following the success of its PD-1 inhibitor Opdivo (nivolumab).
The treatment, developed in collaboration with Bristol-Myers Squibb which costs about $12 500 a month and is estimated to generate global sales of $9.5 billion in 2020, according to reports. It is forecast, sales from the product will more than double Ono’s annual revenue to about $3 billion by March 2018.
Opdivo was first approved in Japan in 2014 to treat unresectable melanoma, later gaining clearance for lung cancer. Ono is now developing Opdivo to treat 20 additional cancer types. The company is seeking approval of the drug for gastric cancer, oesophageal cancer and head and neck cancer from Japanese regulators.
The company has engaged a large sales force to promote Opdivo in Japan.
Anjali Shukla
Related Content
Astellas and Kelonia Therapeutics enter agreement for development of immuno-oncology therapeutics
Astellas Pharma and Kelonia Therapeutics have announced that Xyphos Biosciences (a wholly owned subsidiary of …
NICE shoots down Bristol-Myers Squibb immunotherapy Opdivo for post-surgery skin cancer
NICE has rejected the routine use of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) on the NHS …
Opdivo/Yervoy combo secures FDA approval for malignant pleural mesothelioma
Bristol Myers Squibb’s therapy regimen of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) has secured …